Pulse Biosciences Inc. (PLSE)
NASDAQ: PLSE
· Real-Time Price · USD
16.27
-0.37 (-2.22%)
At close: Sep 17, 2025, 3:59 PM
16.63
2.21%
After-hours: Sep 17, 2025, 05:52 PM EDT
-2.22% (1D)
| Bid | 16.01 |
| Market Cap | 1.09B |
| Revenue (ttm) | 1.66M |
| Net Income (ttm) | -68.03M |
| EPS (ttm) | -1.08 |
| PE Ratio (ttm) | -15.06 |
| Forward PE | -10.93 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 17 |
| Volume | 222,662 |
| Avg. Volume (20D) | 178,280 |
| Open | 16.66 |
| Previous Close | 16.64 |
| Day's Range | 16.00 - 16.75 |
| 52-Week Range | 13.77 - 25.00 |
| Beta | 1.68 |
| Ex-Dividend Date | n/a |
About PLSE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PLSE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PLSE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsPulse Biosciences Inc. is scheduled to release its earnings on
Oct 29, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
-0.46%
PLSE stock has given up its prior gain. Pulse Bios...
Unlock content with
Pro Subscription
1 week ago
-0.46%
Pulse Biosciences shares are trading higher after the company announced that the FDA granted approval for its Investigational Device Exemption, allowing Pulse Biosciences to proceed with the initiation of its nsPFA Cardiac Surgery System Study, NANOCLAMP AF, for the treatment of atrial fibrillation.
19 hours ago · businesswire.com
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or n...
